EQS-Adhoc: Bayer Aktiengesellschaft: Bayer secures 3.0 billion euros to improve capital structure

Leverkusen, July 10, 2026 – Bayer has secured 3.0 billion euros in equity capital to improve its capital structure. The company signed a respective agreement with the global asset management firm Apollo on Friday. Under the agreement, Apollo-managed funds and affiliates will obtain a minority, non-controlling stake in a newly established entity holding Bayer’s long-acting reversible contraceptives (LARC) business. Bayer will retain a majority stake in the entity and will continue to exercise complete operational control over the business. There will be no changes to the LARC strategy or business activities as a result of the investment. The LARC activities will continue to form part of the Bayer Pharmaceuticals Division’s core business, and the entity will remain fully consolidated in the Consolidated Financial Statements of the Bayer Group.

The transaction enhances Bayer’s financial flexibility as the company manages increased liquidity requirements this year related to bond maturities and litigation procedures, while continuing to execute its long-term priorities.

The transaction is expected to close in the third quarter of 2026, subject to approval by antitrust authorities and customary closing conditions.

Forward-Looking Statements
This notification may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.

Contact:
Mrs. Denise Jahn. Bayer AG, Investor Relations, Phone: +49-214-30-72704, e-mail: denise.jahn@bayer.com